Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

NCT ID: NCT00167167

Last Updated: 2017-11-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1995-12-31
• Study Completion Date: 2006-01-31

Brief Summary

In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.

Detailed Description

We will collect immune cells or lymphocytes from the donor's blood using a cell separator. The blood lymphocytes will be given to the subjects through a catheter. If the subjects have no complications of the first course of infusions, we may decide to give them "lymphocytes" aa second time while subjects are in remission in an attempt to prevent their disease from relapsing. A bone marrow test will be taken prior to infusion of lymphocytes as part of the clinical evaluation to receive this treatment. After lymphocyte infusions, a bone marrow will be examined about every three months for the first year to monitor progress from this therapy.

Conditions

Leukemia, Myeloid, Chronic; AML; MDS; Leukemia, Lymphocytic, Acute

Keywords

Donor Lymphocyte Infusion; relapse; post-transplant

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BMT patients

All patients treated.

Group Type: EXPERIMENTAL

Donor Lymphocyte Infusion

Intervention Type: PROCEDURE

Certain immune cells in your donor's blood called "lymphocytes" have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's "lymphocytes" in the hope of activating the recipient's immune system to attack cancer.

Interventions

Donor Lymphocyte Infusion

Certain immune cells in your donor's blood called "lymphocytes" have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's "lymphocytes" in the hope of activating the recipient's immune system to attack cancer.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patients with CML, AML, MDS or ALL relapsed after related or unrelated donor allogeneic marrow transplantation.
• Patients must be within one year of identification of relapse or if beyond that time period, must have some evidence of donor DNA by RFLP or cytogenetics.
• Patients may have evidence of relapse based on molecular, cytogenetic or morphologic criteria.
• CML patients must have cytogenetic evidence of relapse or if Ph negative to start, obvious evidence of relapse other than minimal residual disease.
• Patients must have <30% marrow blasts on a marrow biopsy performed within two weeks of the first donor lymphocyte infusion.
• Patients with >30% blasts can become eligible for donor lymphocytes after reinduction with any standard therapy regimen.
• Patients with AML, MDS or ALL achieving a CR with standard therapy regimens are eligible for this protocol.
• Patients who relapse with their initial disease or develop a second malignancy after related or unrelated donor allogeneic marrow transplantation with other initial diagnoses (such as but not limited to CLL, lymphoma, myeloma, juvenile CML, sarcoma, breast cancer) may also be included in this protocol. Patients will be eligible with or without other adjunct chemotherapy or radiation therapy. Post-transplant lymphomas (often referred to as EBV-associated lymphomas) will be eligible for donor leukocyte infusions on this protocol. Treatment with donor leukocytes under this protocol is restricted to malignant diseases only. Graft failure or relapse of non-malignant disorders is excluded from receiving donor leukocyte infusions on this protocol. Autologous transplant patients who relapse are not eligible for this protocol. Patients with malignant diseases amenable to other curative therapy are not eligible (i.e. skin cancers).

Exclusion Criteria

• Patients with concurrent signs of acute or chronic graft-versus-host disease requiring ongoing treatment at the time of relapse will be ineligible.
• Patients with >30% marrow blasts at the time of therapy will be ineligible.
• Patients on prednisone, cyclosporine, Imuran or other immunosuppressive medications are not eligible until these medications are discontinued for at least 2 weeks without a flare of GVHD.
• CML patients in complete cytogenetic remission who are bcr/abl positive by PCR only are not eligible.

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Masonic Cancer Center, University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Masonic Cancer Center, University of Minnesota

Principal Investigators

Jeffrey Miller, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota Medical Center

Locations

University of Minnesota Medical Center

Minneapolis, Minnesota, United States

Countries

United States

Other Identifiers

MT1995-24

Identifier Type: -

Identifier Source: secondary_id

1996LS146

Identifier Type: -

Identifier Source: secondary_id

9510M10277

Identifier Type: -

Identifier Source: org_study_id